Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 13

Trial Status

Recruiting1
Other2

Role Distribution

Principal Investigator3
PI Rate100%

Activity Timeline

Clinical Trials (3)

NCT07105735Phase 1Recruiting
RN1201 Injection for Autoimmune Diseases Refractory to Standard Therapies
Autoimmune Diseases Refractory to Standard Therapies
PrincipalinvestigatorStart date: 2025-08-15
NCT07113496Phase 1Not Yet Recruiting
RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
B-cell Acute Lymphoblastic Leukemia (B-ALL)Mature B-Cell LymphomaMultiple Myeloma (MM)+3 more
Principalinvestigator
NCT07763938Phase 1Not Yet Recruiting
CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies
Relapsed/Refractory B-cell Malignancies
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Publications (0)

No publications found for this investigator.

Clinical Trials (3)

Showing 3 of 3 trials

NCT07105735Phase 1PrincipalInvestigator

RN1201 Injection for Autoimmune Diseases Refractory to Standard Therapies

Autoimmune Diseases Refractory to Standard Therapies
Recruiting
NCT07113496Phase 1PrincipalInvestigator

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

B-cell Acute Lymphoblastic Leukemia (B-ALL)Mature B-Cell LymphomaMultiple Myeloma (MM)+3 more
Not Yet Recruiting
NCT07763938Phase 1PrincipalInvestigator

CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies

Relapsed/Refractory B-cell Malignancies
Not Yet Recruiting

All 3 trials loaded